cognitive testing News
-
Novatek to support hope for Dementia Charity Gala Jan. 31, 2019
We are SO EXCITED to support the first Charity Gala for Hope for Dementia that will take place on January 31, 2019 in Montreal, QC! Join us for an unforgettable evening of Live Entertainment, Dignitary Speeches from Local & Community Leaders and Touching Story-Telling to support Hope for Dementia! Hope for Dementia is a non-profit organization working to support the cause of safeguarding ...
-
Computerized Cognition Test Provides Better Assessment than Observation
Research published in the Journal of Alzheimer’s Disease this week suggests healthy older adults are less capable of observing their own cognitive decline over an 18 month period than Cogstate’s computerized brief battery (CBB). The study, conducted by neuropsychologists, also indicated that close family members were unable to perceive decline in the cognitive behavior of their ...
By IOS Press
-
Multi-Type Animal Cognitive Behavioral Tests for Disease Research
In the pursuit of advancing disease research and its treatment, animal cognitive behavior is studied in a wide range of animal species. The innovative multi-type animal cognitive behavioral tests are set to complement disease research methodology, enabling scientists to gain deeper insight into the complexities of cognitive functioning and its implications in various pathological conditions. ...
By Protheragen
-
Novatek’s Cognistat Wins Research Poster Award at 6th National Annual Conference of Indian Association of Clinical Psychologists
It is with great privilege that we announce that the All India Institute of Medical Sciences, New Delhi (AIIMS) Research Poster on Cultural Adaptation of Cognistat Computerized Cognitive Assessment Test was awarded the best research poster at the 46th National Annual Conference of Indian Association of Clinical Psychologists in Chandigarh, India February 21-23, 2020. “The latest technology ...
-
Altoida Partners With GN Group to Research and Develop New Cognitive Assessment Technology to Detect Mild Cognitive Impairment
Altoida, Inc. an AI company pioneering next-generation neurological disease diagnostics, and GN Group, a global leader in intelligent audio solutions, have signed a multi-year strategic partnership to research and develop new digital biomarkers for identifying Mild Cognitive Impairment (MCI). The research will serve as the backbone for new augmented reality tools to help at-risk individuals gain ...
-
JAMA Highlights Success of BrainScope`s EEG-based Concussion Index As Reliable Indicator of Concussion
JAMA Network Open has published "Validation of a Machine Learning Brain Electrical Activity-Based Index to Aid in Diagnosing Concussion Among Athletes," a ground-breaking study on the accuracy of the BrainScope FDA-cleared biomarker, the Concussion Index, to indicate the likelihood and severity of concussive brain injury and to aid in evaluating an athlete's readiness to return to play. "What ...
-
NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the University of California, Los Angeles (UCLA) led by Professor Sandra Loo received a National Institutes of Health (NIH) grant to conduct a double-blind randomized controlled trial of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD). The trial will enroll up to 225 children with moderate ...
-
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to commence the largest trial of external Trigeminal Nerve Stimulation (eTNS) ever conducted. The clinical trial ...
-
Appointment of Non-Executive Director and additional key hires
Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the appointment of Dr Guy Wood-Gush as a Non-Executive Director of the Company, effective immediately, and two key hires: Angus Sturrock as Technical Operations and Project Manager, and Dr Chris Papasavvas as a Senior Data Scientist. Investing in key hires ...
-
Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease
The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing sex-based differences using digital biomarker data collected from Altoida’s ...
-
Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease
The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing sex-based differences using digital biomarker data collected from Altoida’s ...
-
Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for its Series A round with new and existing investors. The investment was co-led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, ...
-
Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis
Four separate research reports presented at premier Alzheimer’s disease and aging conferences add to the increasing set of details about the accuracy and clinical usefulness of the PrecivityAD™ blood test from C2N Diagnostics. The PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive impairment. The test helps physicians determine the ...
-
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has executed a Master Services Agreement (MSA) with Societal CDMO, Inc. (NASD: SCTL), a bi-coastal contract development and manufacturing ...
By Cingulate
-
C2N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex ...
-
PERKINELMER AND PREDICTIVE DIAGNOSTICS ANNOUNCE DISCOVERY OF BLOOD BIOMARKERS FOR ALZHEIMER’S DISEASE
Results of Joint Study Presented at the American Association for Clinical Chemistry Conference BOSTON & VACAVILLE, CALIFORNIA , April 19, 2005 – PerkinElmer Inc. (NYSE: PKI ), a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc., a wholly owned subsidiary of Large Scale Biology Corporation (NASDAQ: LSBC), announced ...
-
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the ...
By Cingulate
-
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the completion of its study assessing the effect of food on absorption of its lead candidate CTx-1301, an investigational medication for the ...
By Cingulate
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you